EUVIMEDEUVIMED entdecken
Leserbrief

Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to Abrocitinib

Ashley Vander Does, Gil Yosipovitch

Dermatitis® · 2023

DOI: 10.1089/derm.2022.0065 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Dermatitis®, 2023. Verfasst von Ashley Vander Does und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Phillip Frost Department of Dermatology and Miami Itch Center, University of Miami, Miami, FL, USA. Hauptthemen laut MEDLINE: Prurigo, Neurodermatitis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrurigoNeurodermatitisHumansPruritusPyrimidinesSulfonamides

Substanzen

abrocitinibPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Dr. Phillip Frost Department of Dermatology and Miami Itch Center, University of Miami, Miami, FL, USA.

Zitieren

APA

Vander Does, A., & Yosipovitch, G. (2023). Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to Abrocitinib. Dermatitis®. https://doi.org/10.1089/derm.2022.0065

Vancouver

Vander Does A, Yosipovitch G. Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to Abrocitinib. Dermatitis®. 2023. doi:10.1089/derm.2022.0065

BibTeX
@article{VanderDoes2023,
  author = {Vander Does, Ashley and Yosipovitch, Gil},
  title = {Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to Abrocitinib},
  journal = {Dermatitis®},
  year = {2023},
  doi = {10.1089/derm.2022.0065}
}
Kostenlos starten →